Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study
- PMID: 26179339
- DOI: 10.1111/dar.12308
Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study
Abstract
Introduction and aims: Experiences of buprenorphine-naloxone (BNX) sublingual film injection are not well documented or understood. We examined how people who inject BNX film seek and share information about this practice, document the methods used to prepare BNX film for injection, and report participants' experiences of this practice.
Design and methods: Interviews were (n = 16) conducted with people who indicated that they had injected BNX film since its introduction onto the Australian market. Semistructured interviews were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the data using qualitative description methodology.
Results: Participants largely reported similar BNX film preparation techniques, although the texture of BNX film during preparation to inject was reported to be unusual (gluggy), and there were many varied accounts associated with the amount of water used. Physical harms reported as associated with injecting BNX film were described (including local and systemic issues); participants reported injecting the film to enhance its immediate effects, yet generally reported that sublingual administration provided longer-lasting effects.
Discussion and conclusions: Understanding knowledge acquisition about injecting new formulations of opioid substitution therapy is crucial in developing more effective harm-reduction strategies. Dissemination by peer networks to those who are currently or planning to inject BNX film regarding the 'gelatine like' texture when mixing, using only cold water and double filtering is important to ensure safer injecting practices. Findings from this study highlight the importance of peer networks for the dissemination of harm-reduction information. Introduction of new formulations internationally requires more qualitative studies to inform safer practices.
Keywords: buprenorphine-naloxone; harm reduction; intravenous drug abuse; patient non-adherence; qualitative research.
© 2015 Australasian Professional Society on Alcohol and other Drugs.
Similar articles
-
The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.Drug Alcohol Rev. 2015 Nov;34(6):603-10. doi: 10.1111/dar.12277. Epub 2015 May 6. Drug Alcohol Rev. 2015. PMID: 25950232
-
The diversion and injection of a buprenorphine-naloxone soluble film formulation.Drug Alcohol Depend. 2014 Mar 1;136:21-7. doi: 10.1016/j.drugalcdep.2013.12.005. Epub 2014 Jan 8. Drug Alcohol Depend. 2014. PMID: 24461476
-
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412801 Clinical Trial.
-
A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.J Opioid Manag. 2021;17(7):141-152. doi: 10.5055/jom.2021.0651. J Opioid Manag. 2021. PMID: 34520035 Review.
-
Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.Adolesc Med State Art Rev. 2014 Aug;25(2):251-65. Adolesc Med State Art Rev. 2014. PMID: 27132312 Review. No abstract available.
Cited by
-
Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.JAMA Netw Open. 2023 Jun 1;6(6):e2318487. doi: 10.1001/jamanetworkopen.2023.18487. JAMA Netw Open. 2023. PMID: 37318805 Free PMC article. Review.
-
Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.Harm Reduct J. 2022 Oct 13;19(1):113. doi: 10.1186/s12954-022-00695-5. Harm Reduct J. 2022. PMID: 36229831 Free PMC article. Review.
-
Notes from the Field: Emergency Visits for Complications of Injecting Transmucosal Buprenorphine Products - United States, 2016-2018.MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1102-1103. doi: 10.15585/mmwr.mm6932a5. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32790665 Free PMC article. No abstract available.
-
Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.Hand (N Y). 2017 Sep;12(5):507-511. doi: 10.1177/1558944716672198. Epub 2016 Oct 3. Hand (N Y). 2017. PMID: 28832211 Free PMC article.
-
A New Tool to Tackle the Opioid Epidemic: Description, Utility, and Results from the Maine Diversion Alert Program.Pharmacotherapy. 2017 Jul;37(7):791-798. doi: 10.1002/phar.1952. Epub 2017 Jun 30. Pharmacotherapy. 2017. PMID: 28543168 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Medical

